S. Shigeta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
S. Shigeta has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
K Konno
Department of Microbiology, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan
3 shared publicationsH Kato
Tsukuba Research Laboratory, Toagosei, Tsukuba, 300-2611, Japan
2 shared publicationsE Kodama
Department of Microbiology, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan
1 shared publicationH Aikawa
1 shared publicationH Suzuki
1 shared publicationK Shimotohno
Institute for Virus Research, Kyoto University, Sakyo-ku Shogoin, Kyoto 606, Japan
1 shared publication
Latest Publications
- 1 January 2002
- Published by Taylor & Francis in Xenobiotica
- Vol. 32 (1) , 19-27
Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat
1. RD3-0028, a benzodithiin compound, has potent antiviral activity against respiratory syncytial virus (RSV) in cell culture. The compound also inhibits growth of RSV and improves pathologic changes of interstitial pneumonia in the immunosuppressed mouse when delivered by small-particle aerosol. 2. In the present study, the absorption, distribution and excretion of 14C-RD3-0028 were compared in rat following either a single aerosol treatment or oral administration. 3. The plasma concentration was maintained at the same level from 5 min to 1 h, and decreased with a half-life of 2.2 +/- 0.1 h for 1-8 h. 4. The excretion of radioactivity in the urine and faeces at 24 h after aerosol treatment was 89.3 and 4.5%, respectively, indicating that almost all the radioactivity was rapidly excreted in the urine. The excretion of total radioactivity was 98.9% within 168 h. 5. The concentrations of radioactivity in the lung and trachea following aerosol treatment were higher than those in other tissues, and were detected even at 72 h. 6. These results suggest that the aerosol treatment might be useful for delivering RD3-0028 to the respiratory tract of RSV-infected patients.
- 1 January 2002
- Published by Taylor & Francis in Xenobiotica
- Vol. 32 (1) , 19-27
Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat
1. RD3-0028, a benzodithiin compound, has potent antiviral activity against respiratory syncytial virus (RSV) in cell culture. The compound also inhibits growth of RSV and improves pathologic changes of interstitial pneumonia in the immunosuppressed mouse when delivered by small-particle aerosol. 2. In the present study, the absorption, distribution and excretion of 14C-RD3-0028 were compared in rat following either a single aerosol treatment or oral administration. 3. The plasma concentration was maintained at the same level from 5 min to 1 h, and decreased with a half-life of 2.2 +/- 0.1 h for 1-8 h. 4. The excretion of radioactivity in the urine and faeces at 24 h after aerosol treatment was 89.3 and 4.5%, respectively, indicating that almost all the radioactivity was rapidly excreted in the urine. The excretion of total radioactivity was 98.9% within 168 h. 5. The concentrations of radioactivity in the lung and trachea following aerosol treatment were higher than those in other tissues, and were detected even at 72 h. 6. These results suggest that the aerosol treatment might be useful for delivering RD3-0028 to the respiratory tract of RSV-infected patients.
- Open Access
- 1 August 1999
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 10 (4) , 195-209
Anti-Herpesvirus Activities and Cytotoxicities of 2-Thiopyrimidine Nucleoside Analogues in Vitro
Twenty 2-thiopyrimidine nucleoside analogues were synthesized and examined for inhibitory activity against herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VZV), human cytomegalovirus (HCMV) and thymidine kinase-deficient HSV (HSV-TK) replication in vitro. 2-thiouracil (thymine) arabinoside, 2′-deoxy-2-thiouridine (or 2-thiothymidine) and their 5-halogenated derivatives showed anti-HSV activity in both RPMI8226 (human B-lymphoblastoid cells) and MRC-5 (human embryo lung cells). 2′-deoxy-5-halogenated-2-thiocytidines were also inhibitory against HSV, whereas 2-thiocytosine arabinoside and its derivatives were not inhibitory against HSV replication, except 5-bromo and 5-iodo congeners (TN-31, TN-32). Substitution of the halogen atom at the 5-position of the pyrimidine rings to an atom with a higher molecular weight increased anti-HSV and VZV activities, except for the anti-HSV activity of 2-thiouracil arabinosides. 2′-deoxy-5-methyl-, and 2′-deoxy-5-iodo-2-thiouridines (TN-17, TN-44) showed the most potent anti-HSV activity, and 2′-deoxy-5-chloro- and 2′-deoxy-5-bromo-2-thiocytidines were potent inhibitors of VZV replication. However, none of the compounds inhibited HCMV and HSV-TK− replication. TN-31 and TN-32 were shown to inhibited HCMV and HSV-TK− as well as HSV and VZV replication. The cytotoxicity of the 2-thiopyrimidine nucleoside analogues was less than that of the 2-oxy-congeners of the compounds (5-iodo-2′-deoxyuridine, 5-iodo-2′-deoxycytidine, thymine arabinoside and cytosine arabinoside). The selectivity index of 2′-deoxy-5-iodo-2-thiouridine (TN-44) was higher than that of 5-iodo-deoxyuridine. TN-17 and TN-44 were not cytotoxic to resting or stimulated human peripheral blood mononuclear cells at 400 μ, although TN-32 was cytotoxic at a concentration of 20 μ.
- 1 August 1999
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 10 (4) , 195-209
Open AccessAnti-Herpesvirus Activities and Cytotoxicities of 2-Thiopyrimidine Nucleoside Analogues in Vitro
Twenty 2-thiopyrimidine nucleoside analogues were synthesized and examined for inhibitory activity against herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VZV), human cytomegalovirus (HCMV) and thymidine kinase-deficient HSV (HSV-TK) replication in vitro. 2-thiouracil (thymine) arabinoside, 2′-deoxy-2-thiouridine (or 2-thiothymidine) and their 5-halogenated derivatives showed anti-HSV activity in both RPMI8226 (human B-lymphoblastoid cells) and MRC-5 (human embryo lung cells). 2′-deoxy-5-halogenated-2-thiocytidines were also inhibitory against HSV, whereas 2-thiocytosine arabinoside and its derivatives were not inhibitory against HSV replication, except 5-bromo and 5-iodo congeners (TN-31, TN-32). Substitution of the halogen atom at the 5-position of the pyrimidine rings to an atom with a higher molecular weight increased anti-HSV and VZV activities, except for the anti-HSV activity of 2-thiouracil arabinosides. 2′-deoxy-5-methyl-, and 2′-deoxy-5-iodo-2-thiouridines (TN-17, TN-44) showed the most potent anti-HSV activity, and 2′-deoxy-5-chloro- and 2′-deoxy-5-bromo-2-thiocytidines were potent inhibitors of VZV replication. However, none of the compounds inhibited HCMV and HSV-TK− replication. TN-31 and TN-32 were shown to inhibited HCMV and HSV-TK− as well as HSV and VZV replication. The cytotoxicity of the 2-thiopyrimidine nucleoside analogues was less than that of the 2-oxy-congeners of the compounds (5-iodo-2′-deoxyuridine, 5-iodo-2′-deoxycytidine, thymine arabinoside and cytosine arabinoside). The selectivity index of 2′-deoxy-5-iodo-2-thiouridine (TN-44) was higher than that of 5-iodo-deoxyuridine. TN-17 and TN-44 were not cytotoxic to resting or stimulated human peripheral blood mononuclear cells at 400 μ, although TN-32 was cytotoxic at a concentration of 20 μ.
- Open Access
- 1 December 1997
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 8 (6) , 541-544
Novel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives
This study evaluated the inhibitory effects of 2,4,6-trihydroxy,3-nitro-benzamide (THNB) derivatives against hepatitis C virus (HCV). protease and other human serine proteases. The inhibitory efficacy was tested with a reversed-phase HPLC assay system using a NS3-NS4A fusion protein as the HCV protease and a synthetic peptide substrate that mimics the NS5A-5B junction. Twelve THNB derivatives showed more than 50% inhibition at 100 μg mL-1. The most potent derivative was RD3-4082, with 50% inhibition at a concentration of 2.3 μg mL-1; this concentration was lower than those of other protease inhibitors reported previously. The most selective derivative was RD2-4039, with 50% inhibition at a concentration of 32.8 μg mL-1, a lower concentration than those against other serine proteases (chymotrypsin, trypsin, plasmin and elastase). These results suggest that the RD2-4039 skeleton is an important structure for inhibitory activity against the HCV protease NS3-NS4A.
- 1 December 1997
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 8 (6) , 541-544
Open AccessNovel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives
This study evaluated the inhibitory effects of 2,4,6-trihydroxy,3-nitro-benzamide (THNB) derivatives against hepatitis C virus (HCV). protease and other human serine proteases. The inhibitory efficacy was tested with a reversed-phase HPLC assay system using a NS3-NS4A fusion protein as the HCV protease and a synthetic peptide substrate that mimics the NS5A-5B junction. Twelve THNB derivatives showed more than 50% inhibition at 100 μg mL-1. The most potent derivative was RD3-4082, with 50% inhibition at a concentration of 2.3 μg mL-1; this concentration was lower than those of other protease inhibitors reported previously. The most selective derivative was RD2-4039, with 50% inhibition at a concentration of 32.8 μg mL-1, a lower concentration than those against other serine proteases (chymotrypsin, trypsin, plasmin and elastase). These results suggest that the RD2-4039 skeleton is an important structure for inhibitory activity against the HCV protease NS3-NS4A.
- 1 March 1994
- Vol. 34 (3) , 224-8
[Effect of physostigmine on acetylcholine and monoamine metabolites in rat frontal cortex with lesions of the nucleus basalis of Meynert].
Acetylcholine (ACh) and monamine (MA) metabolites were collected from the frontal cortex of free moving rats, using a microdialysis technique. In rats subjected to bilateral ibotenic acid lesioning of the nucleus basalis of Meynert (nbM), ACh release was markedly decreased, while DOPAC, HVA and 5-HIAA were not affected. Physostigmine (0.3 mg/kg, IP) increased ACh concentration in the brain dialysate, and the rate of ACh increase was lower in nbM-lesioned rats than that in unoperated rats. Physostigmine also increased the concentration of MA metabolites in both nbM-lesioned and unoperated rats equally. The results indicate that there may be some interaction between non nbM-originated cholinergic systems and monoaminergic systems in the frontal cortex.
- 1 March 1994
- Vol. 34 (3) , 224-8
[Effect of physostigmine on acetylcholine and monoamine metabolites in rat frontal cortex with lesions of the nucleus basalis of Meynert].
Acetylcholine (ACh) and monamine (MA) metabolites were collected from the frontal cortex of free moving rats, using a microdialysis technique. In rats subjected to bilateral ibotenic acid lesioning of the nucleus basalis of Meynert (nbM), ACh release was markedly decreased, while DOPAC, HVA and 5-HIAA were not affected. Physostigmine (0.3 mg/kg, IP) increased ACh concentration in the brain dialysate, and the rate of ACh increase was lower in nbM-lesioned rats than that in unoperated rats. Physostigmine also increased the concentration of MA metabolites in both nbM-lesioned and unoperated rats equally. The results indicate that there may be some interaction between non nbM-originated cholinergic systems and monoaminergic systems in the frontal cortex.
- 1 January 1982
- Vol. 28, 93-103
Antibody dependent cellular protection against the cell to cell spread of varicella- zoster virus.
- 1 January 1982
- Vol. 28, 93-103
Antibody dependent cellular protection against the cell to cell spread of varicella- zoster virus.